Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open Gastroenterology"
DOI: 10.1136/bmjgast-2023-001105
Abstract: Background We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease (IBD) centre. Methods All adult… read more here.
Keywords: intravenous subcutaneous; switching patients; cost; costs switching ... See more keywords
Delays in switching patients onto second-line antiretroviral treatment at a public hospital in eThekwini, KwaZulu-Natal
Sign Up to like & getrecommendations! Published in 2017 at "Southern African Journal of HIV Medicine"
DOI: 10.4102/sajhivmed.v18i1.696
Abstract: Background South Africa has one of the largest antiretroviral treatment (ART) programmes globally. In addition to increasing access to ART, it is important that the health system also focuses on the appropriate management of patients… read more here.
Keywords: delays switching; line; switching patients; line art ... See more keywords